In two previous studies we found an association between HTR2C polymorphisms and the prevalence of the metabolic syndrome in patients using antipsychotics. In this study, we set out to replicate our findings in a third separate sample of patients. Data for this cross-sectional study came from the ongoing Pharmacotherapy Monitoring and Outcome survey study, investigating the association between schizophrenia and metabolic or cardiovascular risk factors. Primary end point was the prevalence of the metabolic syndrome. Primary determinants were two polymorphisms in the HTR2C gene: rs3813929 (À759 C/T) and rs1414334:C4G. Carriership of the variant rs1414334 C-allele was significantly associated with an increase prevalence of the metabolic syndrome (odds ratio (OR) 3.73; 95% confidence interval (CI) 1.29-10.79, P ¼ 0.015). No association was found between the HTR2C À759 C/T polymorphism and the metabolic syndrome. This study confirms previous findings that the variant C-allele of the rs1414334 polymorphism is associated with the metabolic syndrome.
Introduction
It has been shown that the prevalence of the metabolic syndrome is increased in patients with schizophrenia compared with the general population. 1 In our own schizophrenic patient population the prevalence of the metabolic syndrome is 36%, compared with 15.5% in the general population. 2, 3 The mechanism behind the metabolic abnormalities is not entirely clear. 4 The high interindividual differences suggest that genetic make-up is a modulating factor. One of the potential genetic determinants is genetic variation in the X-chromosomal gene coding for the serotonergic 2C-receptor (HTR2C), as studies have shown that HTR2C knockout-mice become hyperphagic and HTR2C agonists reduce appetite in humans. 5, 6 Furthermore, several studies found a significant association between HTR2C polymorphisms and metabolic abnormalities, including antipsychotic-induced weight gain. Most studies investigated the HTR2C rs3813929 (À759 C/T) polymorphism, although other HTR2C polymorphisms were studied as well. 5 (rs1414334:C4G) and the metabolic syndrome in patients using antipsychotics in two previously reported studies. 8, 9 In a cross-sectional study with 112 schizophrenic inpatients using antipsychotic drugs, we found an association between HTR2C polymorphisms and the metabolic syndrome. This association looked particularly strong in patients carrying the variant C-allele of the rs1414334 polymorphism (odds ratio (OR) 4.09; 95% confidence interval (CI) 1.41-11.89).
In a cross-sectional replication study with 164 in-patients using antipsychotics, we could not confirm the association between the variant C-allele of the rs1414334 polymorphism and prevalence of the metabolic syndrome (OR 2.35; 95% CI 0.96-5.77), although the association showed a trend towards significance. A pooled analysis of both study populations, making a total of 276 patients, did show a significant association with the metabolic syndrome (OR 2.35; 95% CI 1. 19-4.62) .
A further analysis of individual antipsychotics showed that the variant rs1414334 C-allele was specifically associated with the metabolic syndrome in patients using clozapine (OR 9.20; 95% CI 1.95-43.45) or risperidone (OR 5.35; 95% CI 1.26-22.83). In both studies we did not find an association between the HTR2C 759C/T polymorphism and prevalence of the metabolic syndrome.
The primary objective of this study was to attempt a second replication of the association between HTR2C polymorphisms and the metabolic syndrome in an independent sample of patients using antipsychotics. Secondary objectives were possible associations between HTR2C polymorphisms and individual parameters contributing to the metabolic syndrome.
Materials and methods

Setting
Patients were included from an ongoing 'Pharmacotherapy Monitoring and Outcome survey' (PHAMOUS). PHAMOUS is an initiative from the Rob Giel research centre, a number of Mental Healthcare institutions and the Department of Pharmacotherapy and Pharmaceutical Care from the University of Groningen. PHAMOUS combines a yearly somatic screening with routine outcome assessment in patients using antipsychotics. Risk factors for cardiovascular and metabolic complications are monitored and effectiveness of antipsychotic treatment is evaluated in this survey. Patients included in this study originated from the northern part of the Netherlands. A detailed description of the study design can be found on http://www.phamous.eu.
Design and patients
A cross-sectional design was used to investigate the association between HTR2C variants and the metabolic syndrome in patients diagnosed with schizophrenia, schizoaffective or schizophreniform disorder or psychotic disorder. Diagnosis was performed by the treating psychiatrists according to the DSM-IV criteria. Patients were eligible for inclusion in this study if they used one or more antipsychotic drugs, were 18 years or older and diagnosed with the above-mentioned disorders. After complete description of the study to the patients, informed consent was obtained and blood was drawn for genotyping.
Outcome measures
Primary end point of the study was the presence of the metabolic syndrome. Diagnosis of the metabolic syndrome was based on the definition by the National Cholesterol Education Program's Adult Treatment panel III (NCEP:ATP IIIa). 10 The metabolic syndrome was diagnosed in all patients when three or more of the following five metabolic criteria were met: waist circumference X102 cm (male) or X88 cm (female), triglycerides X1. 7 11 With respect to triglyceridelowering therapy or HDL-increasing therapy, it was decided to allocate fibrates specifically to the triglyceride category and statins to the HDL category. Allocating both fibrates and statines to both triglyceride and HDL categories would have led to an overestimation of the metabolic syndrome, as treatment with a statin or a fibrate would have led to a diagnosis of the metabolic syndrome almost immediately. Secondary end points were the separate metabolic parameters as mentioned above.
Determinants
Primary determinants were genotypes of polymorphisms flanking, or within, the X-linked HTR2C gene. The following two polymorphisms were investigated: the rs3813 929:C4T (À759 C/T) polymorphism located in the promoter region and the rs1414334:C4G polymorphism in intron 5 of the HTR2C gene close to the 3 0 UTR. The HTR2c rs1414334 polymorphism was chosen because of its association with the metabolic syndrome in our previous two studies, and the rs3813929 (759 C/T) polymorphism was chosen because of the multiple studies associating this polymorphism with antipsychotic-induced weight gain. It has been shown that the 759 C/T polymorphism affects the HTR2c transcription rate, with the 759 T-allele leading to a higher expression of the 5HT 2C -receptor. 12 Therefore, patients carrying the 759 T-allele will likely be protected against weight gain caused by HTR2c inhibition by antipsychotics. The intronic position of the rs1414334 polymorphism suggests that this polymorphism is nonfunctional. It is possible, however, that this polymorphism is in linkage with another polymorphism that is associated with the metabolic syndrome and therefore serves as a marker, or possibly changes transcriptional regulation. 13 It should be noted with regard to HTR2C polymorphism nomenclature that for reasons of clarity, we use the nomenclature and nucleotide numbering at the genomic HTR2C polymorphisms and the metabolic syndrome AJ Risselada et al level according to the guidelines of the Human Genome Variation Society (http://www.hgvs.org) as well as the 'traditional' nomenclature and numbering used in previous publications. The rs1414334 polymorphism allele C is described as the ancestral allele (dbSNP database; http:// www.ncbi.nlm.nih.gov/SNP). However, in western and northern Europeans, allele G appears to be the major allele, which is confirmed in our earlier research. 8, 9 In the analysis we therefore considered the C-allele as the variant allele. For the Asians and Africans in our study, the variant rs1414334 allele would actually be the G-allele.
DNA isolation and genotyping
Genomic DNA of patients was isolated from EDTA blood using the X-tractor Gene (Corbett Robotics, Corbett Life Science, Westburg, Leusden, The Netherlands) with X-tractor Gene Liquid Sample Reagent Pack (XTR1, SigmaAldrich, Westburg, Leusden, The Netherlands).
The polymorphisms rs3813929 C/T and rs1414334 C/G were determined with allelic discrimination using predeveloped assays (C_27488117_10 and C_7455701_10, respectively, obtained from Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands) according to the protocol supplied by Applied Biosystems. The reaction was carried out in TaqMan universal PCR master mix (Applied Biosystems) in a Taqman 7500 apparatus. The genotyping of these assays was conducted blind to the clinical status of the patients.
Data analyses and statistics
The association between the metabolic syndrome or the individual metabolic parameters and HTR2C genotypes (presence or absence of the variant HTR2C alleles) was investigated with logistic regression. Data were investigated for potential confounding effects of age, ethnicity, DSM-IV diagnosis, gender, duration of illness, weight-increasing co-medication, weight-reducing co-medication and currently used antipsychotic drugs. We included these variables in the multivariate model if they were univariately associated with the primary end point metabolic syndrome at a significance level of Po0.20.
14 Unless stated otherwise, results are expressed as adjusted OR. Data were investigated for interaction between carriership of variant alleles and gender.
We did not include a stratified analysis for individual antipsychotic drugs used at the moment of evaluation because of the cross-sectional design. The presence of the metabolic syndrome could have been caused by previously used antipsychotics, and therefore would not necessarily reflect the metabolic risk for the currently used antipsychotic.
A P-value o0.05 or less was considered as significant. We did not adjust the P-value to the number of tests due to power considerations, because this could increase the type II error rate too much in this hypothesis-driven study. 15 Data were analysed using SPSS 17.0 (Chicago, IL, USA).
Results
In total, 186 patients were recruited for this replication study. Of these patients, 93% were of Caucasian origin. The remaining patients were of Asian, African or mixed origin. The obtained results did not change by leaving out the Asian, African and mixed ethnicities, and therefore we did not exclude these patients from the analysis. Other patient characteristics of this replication study are summarized in Table 1 .
Olanzapine (n ¼ 43 (23%)), risperidone (n ¼ 40 (22%)) and clozapine (n ¼ 31 (17%)) were the most frequently used antipsychotic drugs. The remaining 38% of the patients used aripiprazole (n ¼
Genotype distribution of the polymorphisms did not deviate significantly from Hardy-Weinberg equilibrium (calculated in females) (rs3813929 (À759 C/T) (P ¼ 0.14) and rs1414334:C4G (P ¼ 0.15)). There was no linkage disequilibrium between both polymorphisms (r 2 ¼ 0.04,
Age, gender, duration of illness, currently used antipsychotic drug, weight-increasing co-medication, weight-reducing co-medication and DSM-IV diagnosis were associated with HTR2C polymorphisms and the metabolic syndrome AJ Risselada et al the metabolic syndrome (Po0.2) and corrected for in the multivariate analysis. The interaction term for HTR2C genotype and gender was not significant (P ¼ 0.72). Table 2 shows that carriership of the HTR2C rs1414334 C-allele is significantly associated with an increased risk for the metabolic syndrome (OR 3.73; 95% CI 1.29-10.79, P ¼ 0.015). Table 3 shows a trend for an association between carriership of the variant rs1414334 C-allele and an increased risk for reaching the cutoff points for lowered HDL (OR 2.59; 95% CI 0.96-7.05) and elevated triglyceride levels (OR 2.39; 95% CI 0.98-5.79), respectively). Further analysis showed a significant association for carriership of the variant rs1414334 C-allele and elevated triglyceride concentrations (2.4 vs 1.7 mmol l À1 , P ¼ 0.014), but no association with HDL concentrations was found (1.32 vs 1.28 mmol l À1 , P ¼ 0.72).
Discussion
In this second replication study, we extend the evidence for the association between the HTR2C rs1414334 polymorphism and the prevalence of the metabolic syndrome.
Patients carrying the C-allele of the HTR2C rs1414334 polymorphism are at an increased risk for the metabolic syndrome while taking antipsychotic drugs compared with patients not carrying the HTR2C rs1414334 C-allele (OR 3.73 95% CI 1.29-10.79). Again, in concordance with the other two studies no association was found between the HTR2C À759 C/T polymorphism and the metabolic syndrome.
There are some limitations to these results. First, we recognize that the cross-sectional design is an important limitation, because data on metabolic parameters of the patients at the initiation of antipsychotic drug treatment were not available to us. Therefore, we were unable to analyse data for changes in metabolic parameters over time related to the use of antipsychotic drugs, or correct our data for possible confounders that originated in the period before the inclusion period. This limitation makes it difficult to compare our results with prospective follow-up studies investigating the association between the HTR2C rs3813929 (À759 C/T) polymorphism and metabolic disturbances (weight gain) in psychiatric patients using antipsychotics. 16, 17 It is possible that we did not find significant results for the HTR2C rs3813929:C4T (À759 C/T) polymorphism due to this limitation. Furthermore, the length of antipsychotic treatment was not always known, which could implicate that there was not enough time for the metabolic syndrome to develop in some patients. However, the average duration of illness was around 10 years in our population, with only a few patients (n ¼ 5) being diagnosed less than a year before inclusion in this study. As treatment with antipsychotics is initiated almost immediately after the diagnosis, we believe that the treatment duration of the patients in our population was long enough for the metabolic syndrome to develop.
Second, the sample size of this replication study population was relatively small. The small sample size may have limited the power to detect differences between groups that are only moderate in size resulting in nonsignificant trends. However, this is the third time we found an association between the variant rs1414334 C-allele and the metabolic syndrome in a cross-sectional study with comparable sample sizes. This makes it less likely that the association found is the result of a type I error, but most likely represents a true association finding.
Third, some variables contributing to a patient's risk of the metabolic syndrome, for example, smoking behaviour, Data were adjusted for age, gender, duration of illness, antipsychotic drug, weight-increasing co-medication, weight-reducing co-medication and DSM-IV diagnosis. exercise and diet, were not taken into account. Fourth, in most of the patients no values for fasting plasma glucose were available, and therefore we used HbA1c instead, with a cutoff point of 46.1%. Using HbA1c instead of fasting glucose possibly has some effect on diagnosis of the metabolic syndrome, thereby affecting our results. However, the review study by Bennett et al. 11 showed that a recommended HbA1c cutoff point of 46.1% had similar accuracy as fasting plasma glucose 6.0 mmol l À1 for predicting type 2 diabetes (sensitivity 72.7, specificity 94.7%). Neither in the current study nor in the first replication study did we find a trend towards a positive association between HTR2C polymorphisms and glucose measurements or HbA1c. Therefore, we believe that measurements of glucose or HbA1c do not influence the obtained results.
The main question regarding our current findings is: did we replicate the results of our previous two studies? Using the new ATPIIIa criteria for diagnosis of the metabolic syndrome, combined with HbA1c, we found a significant association between carriership of the variant rs1414334 C-allele and the metabolic syndrome. In our previous two studies, we used a slightly different set of criteria to diagnose the metabolic syndrome. 8, 9 In those two studies, the metabolic syndrome was diagnosed when three or more of the following four metabolic criteria were met: waist circumference 4102 cm (male) or 488 cm (female), triglycerides X1.7 mmol l À1 , HDL cholesterol o1.0 mmol l
À1
(male) or o1.3 mmol l À1 (female) and blood pressure X135/85 mm Hg. However, in these two studies we also corrected for potential confounding effects of drugs with an influence on glucose and lipid homeostasis. As these corrections are similar to the new ATPIIIa criteria, we believe that the results from the presented multivariate data analysis for an association between HTR2C genotype and the metabolic syndrome are comparable with the results of the other two studies and represents a true association. We did not find an association between the 759 C/T genotype and prevalence of the metabolic syndrome. This was unexpected as the 759 C/T polymorphism has been repeatedly associated with antipsychotic-induced weight gain, and weight gain is an important predictor for meeting the criteria for the metabolic syndrome. 12, [16] [17] [18] [19] [20] [21] [22] [23] [24] The fact that this is the third study in which we found an association between prevalence of the metabolic syndrome and HTR2C rs1414334 genotype, but not 759C/T genotype, requires an explanation. We suggest that we are dealing with two different phenotypes in two different phases of the disease with weight gain at the initiation of treatment and the presence (and prevalence) of the metabolic syndrome, after a longer period of treatment with antipsychotic drugs. The studies that found an association between 759 C/T genotype and antipsychotic-induced weight gain were almost exclusively carried out prospectively in first-episode schizophrenic populations, [16] [17] [18] [19] whereas the studies that failed to find this association were most often carried out in populations with treatment-resistant schizophrenia. [21] [22] [23] Studies are warranted to investigate whether the rs1414334 polymorphism also has an impact on antipsychotic-induced weight gain in the populations of the studies that reported a positive association between antipsychotic-induced weight gain and 759 C/T genotype. [16] [17] [18] [19] It would also be warranted to investigate the association between the rs1414334 polymorphism and prevalence of the metabolic syndrome or weight gain in the studies that used a treatment-resistant population, and failed to find an association between weight gain and 759 C/T genotype. [21] [22] [23] Investigating these associations could provide further evidence for the possible impact of the HTR2C rs1414334 genotype on short-term and longterm metabolic complications caused by treatment with antipsychotic drugs.
It is interesting to hypothesize that two polymorphisms located on the same gene coding for the 5HT 2C receptor result in different phenotypes. This could implicate that both polymorphisms have a different effect on receptor functioning or a different interaction with other metabolicregulating systems. One of the explanations could be a different interaction with the leptine system as reported by Templeman et al., 19 Yevtushenko et al., 24 and Gregoor et al.
25
(data submitted).
In conclusion, this study provides further evidence for the association between the HTR2C rs1414334 polymorphism and the metabolic syndrome, confirming previous findings. Studies investigating the possible association between the rs1414334 polymorphism and antipsychotic-induced weight gain are warranted, as well as studies investigating the interaction and genetic linkage between HTR2C genotypes (rs 1414334 and À759 C/T) and other metabolicregulating systems. These studies may explain the observed differences in results between studies investigating the À759 C/T genotype and antipsychotic-induced weight gain and our studies investigating the rs1414334 genotype and the metabolic syndrome.
